Skip to main content
. 2019 Dec 30;19:1272. doi: 10.1186/s12885-019-6485-4

Table 2.

Tumor characteristics at diagnosis according to mammographic density at diagnosis

BI-RADSa a BI-RADS b BI-RADS c BI-RADS d
Estrogen receptor status positive 5 (31.3) 69 (57.5) 89 (63.6) 20 (76.9)
negative 11 (68.8) 47 (39.2) 46 (32.9) 6 (23.1)
missing 4 (3.3) 5 (3.6)
Progesterone receptor status positive 4 (25.0) 44 (36.7) 77 (55.0) 15 (57.7)
negative 12 (75.0) 72 (60.0) 58 (41.4) 11 (42.3)
missing 4 (3.3) 5 (3.6)
HER2 status positive 3 (18.8) 45 (37.5) 38 (27.1) 9 (34.6)
negative 11 (68.8) 68 (56.7) 95 (67.9) 17 (65.4)
missing 2 (12.5) 7 (5.8) 7 (5.0)
Ki67 > 20% (high) 12 (75.0) 89 (74.2) 89 (63.6) 15 (57.7)
<=20% (low) 2 (12.5) 9 (7.5) 25 (17.9) 3 (11.5)
missing 2 (12.5) 22 (18.3) 26 (18.6) 8 (30.8)
FNAb axilla positive FNA 11 (68.8) 80 (66.7) 91 (65.0) 15 (57.7)
negative FNA 8 (6.7) 10 (7.1) 4 (15.4)
inconclusive FNA 1 (6.3) 3 (2.1) 1 (3.8)
no FNA 4 (25.0) 32 (26.7) 35 (25.0) 6 (23.1)
missing 1 (0.7)
Tumor size at diagnosis (mm)c median (IQR) 34 (23–40) 30 (21–40) 35 (25–50) 30 (20–40)

aThroughout the table BI-RADS breast composition is intended

bfine needle aspiration

cMeasured in mammograms or in ultrasound images. When both methods were conclusive an average measure was used